AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$ACOG

Opaleye Management Inc. purchased $309K of ACOG (indirect holdings)

Opaleye Management Inc. purchased 36,940 indirectly-held shares of Alpha Cognition Inc. (ACOG) at an average of $8.35 ($8.23–$8.43, $0.31M total) across 2 trades over 2026-10-15 to 2026-10-16.

Original reporting
SEC EDGAR · Opaleye Management Inc.
Published Oct 19, 2026, 9:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 9:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ACOG
Bullish
medium confidence
Mentioned
$ACOG
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ACOGBullishLow
01

Why it matters

A $309K purchase by a 10% owner modestly raises confidence in Alpha Cognition, but the small amount limits market impact.

02

Market read

The filing provides a fresh, material insider purchase signal for ACOG, but its modest size keeps overall market relevance low.

03

What to watch

Potential hidden motivations such as tax considerations or a pre‑planned 10b5‑1 execution could diminish the signal strength.

Relevance 5/10Novelty 4/10Timing: today

Background

SEC Form 4 filings disclose insider transactions and are primary sources for new ownership changes.

Company-level read

Ticker impact

$ACOGBullishMedium confidence
Context

Opaleye Management Inc. filed a Form 4 showing a $309K open‑market purchase of 36,940 ACOG shares, increasing its stake to over 3.2M shares.

Expected impact

modest upward pressure as the market prices in the insider buying

Evidence & confidence

The transaction size is small ($309K) but represents a 10% owner increasing its holding, which can be viewed positively by traders.

Market effects

Sector

Limited impact on the broader AI/tech sector; primarily a company‑specific signal.

Regional

No significant regional effect; the filing is U.S.‑focused.

Global

Minimal global relevance beyond Alpha Cognition investors.

Counterpoint

What could challenge this read

The purchase may be routine portfolio rebalancing rather than a strong endorsement.

Key entities

  • company
    Alpha Cognition Inc.

    Issuer of the shares purchased.

  • insider
    Opaleye Management Inc.

    Reporting entity and 10% owner.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ACOG insider trading history →

Related articles

$ACOGMed

Alpha Cognition Q2 Earnings Call Highlights

Alpha Cognition (NASDAQ:ACOG) said ZUNVEYL demand rose each month in Q2, with June the strongest month to date, and management attributed growth to demand rather than wholesaler or pharmacy stocking. Payer formulary activation lagged expectations, with payer access the key near-term friction. The company reported BEACON study positive top-line results, lowered 2026 operating expense guidance to $50M-$54M, and had $41.4M cash as of June 30.

yahoo.com
$ACOGHighAI 9/10

Why is Alpha Cognition stock surging today?

Alpha Cognition (ACOG) shares rose about 12.1% pre-open after its Q2 2026 earnings call. ZUNVEYL net product revenue was about $6.0M, up 71% sequentially and from $1.7M in Q2 2025. Net loss narrowed to $8.8M ($0.40/share). Gross product margin was ~94%, and full-year 2026 operating expense guidance was cut to $50M-$54M; profitability target remains 2027.

investing.com
$ACOGMed

Alpha Cognition Receives European Patent Covering ZUNVEYL® for the Treatment of Mild-to-Moderate Alzheimer’s Disease

Alpha Cognition Inc. (NASDAQ: ACOG) said the European Patent Office granted a European patent covering a crystalline solid form of benzgalantamine, the active ingredient in ZUNVEYL, for use in treating mild-to-moderate Alzheimer’s disease. The patent covers specific solid form, compositions, manufacturing and medical-use claims, with potential protection into 2042, subject to requirements.

thestarphoenix.com